Abou-Alfa GK et al. ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. ESMO 2019;Abstract LBA10_PR.

Fan B et al. Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study. ASCO Gastrointestinal Cancers Symposium 2020;Abstract 539.

Goyal L et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov 2019;9(8):1064-79. Abstract

Harding JJ et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov 2018;8(12):1540-7. Abstract

Jiao Y et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013;45(12):1470-3. Abstract

Ong CK et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 2012;44(6):690-3. Abstract

Subbiah V et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21(9):1234-43. Abstract

Valle JW et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov 2017;7(9):943-62. Abstract

Vogel A et al. FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA). ESMO 2019;Abstract LBA40.